|
Spurring New Research For Neglected Diseases
Gerard F. Anderson
A very small proportion of global spending for biomedical research is for neglected diseases. However, neglected diseases account for a sizable percentage of the global burden of disease, especially in low-income countries. For-profit pharmaceutical and biotech companies are unlikely to conduct significant additional research on neglected diseases without financial incentives. This paper examines the benefits of providing a tax credit to encourage companies to conduct preclinical research on neglected diseases in the laboratory or in animals. This strategy could lead to a new generation of treatment options for the people in low-income countries who are susceptible to neglected diseases.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Musgrove and P. J. Hotez
Turning Neglected Tropical Diseases Into Forgotten Maladies
Health Aff.,
November 1, 2009;
28(6):
1691 - 1706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Geraghty
Expanding The Biopharmaceutical Industry's Involvement In Fighting Neglected Diseases
Health Aff.,
November 1, 2009;
28(6):
1774 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
